Clinical bottom line
Tumor-derived neoantigen load is emerging as a putative biomarker influencing the efficacy of personalized cancer vaccines. Early-phase clinical studies and preclinical models suggest that higher neoantigen burden may enhance vaccine-induced antitumor immune responses and improve clinical outcomes in select solid tumors. However, variability in neoantigen prediction, vaccine platforms, and patient immune status currently limits broad clinical application. Personalized neoantigen vaccines warrant further validation in randomized trials to clarify their role in precision immunotherapy and to optimize patient selection.
What the evidence shows
Personalized cancer vaccines targeting tumor-specific neoantigens—mutated peptides unique to an individual’s tumor—represent a promising immunotherapeutic strategy designed to elicit robust, tumor-directed T cell responses. Several vaccine platforms have been explored, including peptide-based, mRNA, adenoviral vector, and virus-like particle formulations, each aiming to present neoantigens effectively to the immune system.
Preclinical studies demonstrate that vaccines formulated with a higher load of validated neoantigens can induce stronger cytotoxic T lymphocyte responses and tumor regression in murine models (Surgical Tumor-Derived Personalized Photothermal Vaccine, 2018; Virus-Like Particle-Based Personalized Neoantigen Nano-Vaccine, 2015). These findings support the hypothesis that neoantigen load correlates with immunogenicity.
Clinical evidence, though preliminary, aligns with these observations. A phase I study of a personalized mRNA vaccine encoding patient-specific neoantigens in advanced esophageal and non-small cell lung cancer patients reported that higher neoantigen burden was associated with enhanced vaccine-induced T cell responses and prolonged progression-free survival in some patients (Clinical Study of Personalized mRNA Vaccine, 2019). Similarly, adenoviral vector-based neoantigen vaccines have shown immunogenicity and safety in early-phase trials, with neoantigen load influencing immune priming efficacy (Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901, 2020).
Additional reports indicate that integrating multiple neoantigens into vaccine constructs may reduce tumor immune escape and recurrence risk by broadening the T cell repertoire (Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01, 2020; Personalized Neoantigen Vaccine Against Cancer, 2022). However, the optimal number and quality of neoantigens required for clinical benefit remain undefined.
Caveats and uncertainty
Despite encouraging data, several challenges temper enthusiasm for immediate clinical adoption. Neoantigen prediction algorithms vary in accuracy, and not all predicted neoantigens elicit effective immune responses. Tumor heterogeneity and immune evasion mechanisms may limit vaccine efficacy even with high neoantigen load.
Most clinical evidence derives from small, early-phase trials lacking control arms, limiting assessment of vaccine impact on survival outcomes. Patient selection bias and heterogeneity in tumor types, prior therapies, and immune competence complicate interpretation.
Moreover, the manufacturing complexity and cost of personalized neoantigen vaccines pose logistical barriers. The time required for neoantigen identification and vaccine production may delay treatment initiation, particularly in aggressive cancers.
Finally, the interplay between neoantigen load and other biomarkers of immunotherapy response, such as tumor mutational burden or PD-L1 expression, is incompletely understood and warrants further study.
How this may change practice
If ongoing and future randomized trials confirm that tumor-derived neoantigen load predicts personalized vaccine efficacy, this biomarker could guide patient selection for neoantigen-based immunotherapies. Incorporating neoantigen load assessment into molecular tumor profiling may become standard to identify candidates most likely to benefit.
Personalized neoantigen vaccines could complement existing immunotherapies, such as checkpoint inhibitors, by enhancing tumor-specific T cell responses, potentially improving outcomes in cancers with moderate immunogenicity.
Clinicians should remain aware of evolving evidence and emerging clinical trials exploring neoantigen vaccines. Referral to specialized centers offering such investigational therapies may be appropriate for eligible patients.
Continued refinement of neoantigen prediction methods, vaccine platforms, and combination strategies will be critical to translating this approach into routine oncology practice.